This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
K Akter , EA Lanza , SA Martin , N Myronyuk , (2011). Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? British Journal of Clinical Pharmacology 71, 365–376.
C Ballard , S Gauthier , A Corbett , C Brayne , (2011). Alzheimer's disease. Lancet 377, 1019–1031.
KA Bates , G Verdile , QX Li , D Ames , (2009). Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Molecular Psychiatry 14, 469–486.
R Deane , Z Wu , A Sagare , J Davis , (2004). LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333–344.
A Gauthier , G Vassiliou , F Benoist , R McPherson (2003). Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. Journal of Biological Chemistry 278, 11945–11953.
DS Geldmacher , T Fritsch , MJ McClendon , G Landreth (2011). A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Archives of Neurology 68, 45–50.
M Gold , C Alderton , M Zvartau-Hind , S Egginton , (2010). Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dementia and Geriatric Cognitive Disorders 30, 131–146.
JJ Goto , RE Tanzi (2002). The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's A beta generation: development of a cell-based model system. Journal of Molecular Neuroscience 19, 37–41.
S Hauser , G Adelmant , P Sarraf , HM Wright , (2000). Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. Journal of Biological Chemistry 275, 18527–18533.
J Herz , DK Strickland (2001). LRP: a multifunctional scavenger and signaling receptor. Journal of Clinical Investigation 108, 779–784.
G Landreth , Q Jiang , S Mandrekar , M Heneka (2008). PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 5, 481–489.
KG Mawuenyega , W Sigurdson , V Ovod , L Munsell , (2010). Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330, 1774.
OR Monro , JB Mackic , S Yamada , MB Segal , (2002). Substitution at codon 22 reduces clearance of Alzheimer's amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiology of Aging 23, 405–412.
M Niemi , JT Backman , M Granfors , J Laitila , (2003). Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 46, 1319–1323.
P Riederer , J Bartl , G Laux , E Grunblatt (2011). Diabetes type II: a risk factor for depression-Parkinson-Alzheimer? Neurotoxicity Research 19, 253–265.
A Sagare , R Deane , RD Bell , B Johnson , (2007). Clearance of amyloid-beta by circulating lipoprotein receptors. Nature Medicine 13, 1029–1031.
M Shibata , S Yamada , SR Kumar , M Calero , (2000). Clearance of Alzheimer's amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. Journal of Clinical Investigation 106, 1489–1499.
M Shinohara , N Sato , H Kurinami , D Takeuchi , (2010). Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance. Journal of Biological Chemistry 285, 22091–22102.
M Ueno , T Nakagawa , B Wu , M Onodera , (2010). Transporters in the brain endothelial barrier. Current Medicinal Chemistry 17, 1125–1138.
O Wirths , G Multhaup , TA Bayer (2004). A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide–the first step of a fatal cascade. Journal of Neurochemistry 91, 513–520.
BV Zlokovic , R Deane , AP Sagare , RD Bell , (2010). Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain. Journal of Neurochemistry 115, 1077–1089.